Recent News

• 12.08.2025 - Protara Announces Closing of $75 Million Public Offering
• 12.05.2025 - Protara Announces Pricing of $75 Million Public Offering
• 12.04.2025 - Protara Announces Proposed Public Offering
• 12.01.2025 - Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025
• 11.18.2025 - Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
• 11.04.2025 - Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
• 10.01.2025 - Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 10.01.2025 - Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 10.01.2025 - Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 12.08.2025 - 8-K Current report
• 12.05.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.04.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.03.2025 - EX-99.1 EX-99.1
• 12.03.2025 - 8-K Current report
• 11.19.2025 - 8-K Current report
• 11.19.2025 - EX-99.1 EX-99.1
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.10.2025 - 8-K Current report
• 11.10.2025 - EX-99.1 EX-99.1